Makes pills that replace injections for rare hormone disorders by engineering molecules that survive stomach acid.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- ScaleRevenue is in the bottom 5% globally
Makes pills that replace injections for rare hormone disorders by engineering molecules that survive stomach acid.
What this company is and how it runs — written from structure, not news.
Crinetics Pharmaceuticals turns injectable hormone therapies into pills by engineering small molecules that survive stomach acid and bind the same receptors that peptide drugs like octreotide and lanreotide target through injection. Because paltusotine demonstrated bioequivalence to those injectables in clinical trials, the FDA approved it under the 505(b)(2) pathway, which means any competitor wanting the same regulatory standing must recruit its own acromegaly patients — a rare disease population — and run the same multi-year trials before the agency will accept their data. That patient-recruitment bottleneck is the thing capital cannot buy around, so the first oral drug through the door effectively occupies the space while competitors wait out their own trial timelines. The whole position rests on the FDA leaving the 505(b)(2) rules unchanged — if the agency tightens what counts as an adequate bioequivalence demonstration for hormone receptor drugs, Crinetics would have to renegotiate the approval that everything else is built on.
How does this company make money?
The company earns money each time a prescription for PALSONIFY is filled through a specialty pharmacy or purchased by a hospital, with prices set against what injectable octreotide and lanreotide cost. It can also collect milestone payments if it licenses any of its pipeline compounds to other companies through partnership deals.
What makes this company hard to replace?
The FDA approval process for PALSONIFY has already been completed under the 505(b)(2) rules, and no competing oral drug has gone through the same process — so there is nothing for a doctor to switch to. Endocrinologists who prescribed paltusotine during clinical trials have an established relationship with the drug and its patient management protocols. The specialty pharmacies that handle rare endocrine patients are already set up to dispense PALSONIFY, creating a distribution infrastructure that a new entrant would have to replicate from nothing.
What limits this company?
Every new hormone target requires its own solution from scratch. The geometry of each receptor is different, so the chemistry team must independently figure out how to build a small molecule that binds tightly enough and survives oral dosing — and that problem cannot be shortcut or shared across programs before clinical trials can even begin.
What does this company depend on?
The company cannot operate without FDA approval for PALSONIFY under the 505(b)(2) pathway. It also depends on its proprietary chemistry for binding somatostatin receptor type 2, its separate platform for synthesizing ACTH receptor antagonists, clinical trial sites that specialize in rare endocrine disorders, and specialty pharmacy networks that distribute orphan drugs to small patient populations.
Who depends on this company?
Patients with acromegaly who take paltusotine daily to suppress hormone activity would have to go back to injectable octreotide or lanreotide if the oral pill became unavailable. Endocrinologists treating congenital adrenal hyperplasia would lose their only oral option for suppressing ACTH and would have to return their patients to corticosteroid management instead.
How does this company scale?
Once the chemistry and receptor-targeting knowledge exist for one hormone program, those methods can be applied to new programs relatively cheaply. What does not scale easily is the clinical side: each new rare endocrine disease requires its own separate FDA discussions, its own set of disease-specific measurements to prove the drug is working, and its own patient recruitment effort — none of which can be automated or combined across programs.
What external forces can significantly affect this company?
Medicare Part D decides how much it will reimburse for specialty oral drugs, and those decisions directly affect whether PALSONIFY is priced competitively against the injectable alternatives it replaces. The European Medicines Agency's policies on orphan drug designations shape whether the company can build a commercial presence outside the US. And any change to FDA guidance on 505(b)(2) requirements for hormone therapies could undermine the regulatory foundation the entire business sits on.
Where is this company structurally vulnerable?
If the FDA rewrites its rules for the 505(b)(2) approval pathway — specifically tightening what counts as adequate proof of equivalence for hormone receptor drugs — the approval that PALSONIFY already holds could be required to meet new, higher standards. That would erase the regulatory wall keeping competitors out of the oral acromegaly market and force Corcept to renegotiate its entire approved position.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three present-state price/volume observations co-occur: Relative Momentum Index positive (5-period gains exceed losses over 14-period window), Money Flow Index positive (positive money flow dominates over 14-period window), and Accumulation/Distribution line elevated (volume-weighted close position above midpoint over 21 weeks). All three are public price-and-volume signals; none reads institutional fund flow data.
Three observations have aligned in the up direction: the Ichimoku-cloud composite is firing on its up-side configuration, the trend-strength composite is in the upper portion of its mapped range, and the volume-weighted-returns sum over the 60-week lookback is net positive.
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph